应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
IND Xtrackers Nifty 500 India ETF
未开盘 02-25 16:00:00 EST
24.43
+0.23
+0.95%
盘后
24.50
+0.07
+0.28%
16:04 EST
最高
24.58
最低
24.26
成交量
7,303
今开
24.35
昨收
24.20
日振幅
1.32%
总市值
488.60万
流通市值
488.60万
总股本
20.00万
成交额
17.89万
换手率
3.65%
流通股本
20.00万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
前沿生物:2027年计划推动1-2款小核酸产品完成IND申报
证券日报 · 02-25 21:05
前沿生物:2027年计划推动1-2款小核酸产品完成IND申报
中国抗体-B(03681):SM17用于治疗IBD的IND获NMPA批准
智通财经 · 02-24 22:01
中国抗体-B(03681):SM17用于治疗IBD的IND获NMPA批准
一份报告砸崩印度IT!AI冲击担忧发酵,印度软件股遭遇大规模抛售
智通财经 · 02-24 15:03
一份报告砸崩印度IT!AI冲击担忧发酵,印度软件股遭遇大规模抛售
长风药业(02652):国家药监局受理ICF004的IND申请
智通财经 · 02-24 06:12
长风药业(02652):国家药监局受理ICF004的IND申请
美国FDA局长抱怨:美国在早期药物研发方面正落后于中国
观察者网 · 02-19
美国FDA局长抱怨:美国在早期药物研发方面正落后于中国
野村:印度央行在2027年前不太可能降息
环球市场播报 · 02-16
野村:印度央行在2027年前不太可能降息
基石药业:CS2009II期临床试验申请获美国FDA批准
人民财讯 · 02-16
基石药业:CS2009II期临床试验申请获美国FDA批准
九源基因(02566):JY54注射液IND申请获CDE正式受理
智通财经 · 02-09
九源基因(02566):JY54注射液IND申请获CDE正式受理
亚盛医药BTK降解剂APG-3288新药临床申请(IND)获CDE许可,全球临床开发再提速
美通社 · 02-06
亚盛医药BTK降解剂APG-3288新药临床申请(IND)获CDE许可,全球临床开发再提速
友芝友生物-B(02496):M 701取得FDA的IND批准
智通财经 · 02-03
友芝友生物-B(02496):M 701取得FDA的IND批准
这家药企又一款新药临床申请获FDA许可,国际化发展持续加速
制药网 · 01-08
这家药企又一款新药临床申请获FDA许可,国际化发展持续加速
港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理
智通财经 · 01-08
港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理
康希诺:2025年公司4款候选产品已获得批准IND/NDA
证券日报 · 01-06
康希诺:2025年公司4款候选产品已获得批准IND/NDA
港股异动 | 复宏汉霖(02696)现涨近9% 公司旗下三款实体瘤创新药IND同期获受理
智通财经 · 01-05
港股异动 | 复宏汉霖(02696)现涨近9% 公司旗下三款实体瘤创新药IND同期获受理
歌礼制药-B(01672)宣布ASC30在糖尿病受试者中的 13周II期研究IND获美国FDA批准
智通财经 · 01-05
歌礼制药-B(01672)宣布ASC30在糖尿病受试者中的 13周II期研究IND获美国FDA批准
海思科(002653.SZ):“HSK50042”、“HSK55879”创新药IND申请获受理
智通财经 · 2025-12-30
海思科(002653.SZ):“HSK50042”、“HSK55879”创新药IND申请获受理
康宁杰瑞制药-B(09966):JSKN033的一项II期临床试验的IND申请获CDE正式受理
智通财经 · 2025-12-29
康宁杰瑞制药-B(09966):JSKN033的一项II期临床试验的IND申请获CDE正式受理
友芝友生物-B(02496):Y225(艾美赛珠单抗注射液)取得NMPA的IND批准
智通财经 · 2025-12-24
友芝友生物-B(02496):Y225(艾美赛珠单抗注射液)取得NMPA的IND批准
和誉-B(02256):口服小分子KRAS G12D抑制剂ABSK141的IND获NMPA批准
智通财经 · 2025-12-24
和誉-B(02256):口服小分子KRAS G12D抑制剂ABSK141的IND获NMPA批准
海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理
智通财经 · 2025-12-22
海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理
加载更多
公司概况
公司名称:
Xtrackers Nifty 500 India ETF
所属市场:
NASDAQ
上市日期:
--
主营业务:
荷兰国际集团是在1991年由荷兰国民人寿保险公司和荷兰邮政银行集团合并组成的综合性财政金融集团。据美国财富(FORTUNES)杂志统计,以资产净值计算,荷兰国际集团位居全球500家大企业的第64位。在提供综合性金融财经业务方面(银行与保险业务),居世界第三位。目前,该集团在世界上65个国家和地区设有分支机构,雇员超过10万人。2000年,该集团取得税后净利润49亿欧元,同比增长24%。截至2000年底,集团资产总额达5030亿欧元。 管理结构: 在董事会下面设有四个管理运作核心,荷兰总部;国际金融财经业务部;企业和资本市场部;资产管理部。 集团总部:负责荷兰本国市场上的全部保险和银行业务。 国际金融财经业务部:所有荷兰本土以外的国际保险业、零售银行业和商业银行业的运作皆由该中心管理。其保险业务划分三大地区:欧洲和拉丁美洲、北美洲、亚澳地区。银行业务则由中心统一管理。 企业及资本市场部:所有国际货币和资本市场管理部门都由该部门管理。包括国际银行网络以及金融产品、贸易、销售、投资银行、企业银行、风险管理及调研的各项业务。 资产管理部:该部门承担企业投资者的资产和帐目管理、提供个人国际银行服务以及集团公司的保险业务的资产管理。房地产业务和信托业务也属于这个部门管理。该部门同时管理荷兰国际集团各个公司的投资基金。
发行价格:
--
{"stockData":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":24.43,"timestamp":1772053200000,"preClose":24.2,"halted":0,"volume":7303,"hourTrading":{"tag":"盘后","latestPrice":24.4989,"preClose":24.43,"latestTime":"16:04 EST","volume":1,"amount":24.43,"timestamp":1772053467816,"change":0.0689,"changeRate":0.00282,"amplitude":0},"delay":0,"changeRate":0.009504132231404977,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"未开盘","change":0.23,"latestTime":"02-25 16:00:00 EST","open":24.35,"high":24.58,"low":24.26,"amount":178883.800892,"amplitude":0.013223,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772096400000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":24.2,"sharesOutstanding":200001,"nav":24.036,"aum":4807181.17,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.4989,"preClose":24.43,"latestTime":"16:04 EST","volume":1,"amount":24.43,"timestamp":1772053467816,"change":0.0689,"changeRate":0.00282,"amplitude":0},"volumeRatio":3.539304},"requestUrl":"/m/hq/s/IND","defaultTab":"news","newsList":[{"id":"2614806320","title":"前沿生物:2027年计划推动1-2款小核酸产品完成IND申报","url":"https://stock-news.laohu8.com/highlight/detail?id=2614806320","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614806320?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:05","pubTimestamp":1772024700,"startTime":"0","endTime":"0","summary":"一是高端仿制药领域,两款分别面向美国、中国市场的产品,计划于未来两年内获批上市,为公司带来现金流支撑;二是HIV领域,持续推进差异化产品研发,力争推出1款新的创新药品种;三是小核酸领域,核心推进已公开的FB7013、FB7011、FB7023、FB7033四款管线,积极争取推动FB7023/FB7033中的一款完成IND申报,同时计划推进一款肝外递送相关早期产品达到PCC阶段;2027年计划推动1-2款小核酸产品完成IND申报,更多肝外递送早期产品达到PCC阶段。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-25/doc-inhnzvzk2138518.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-25/doc-inhnzvzk2138518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","IND","688221"],"gpt_icon":0},{"id":"2613717630","title":"中国抗体-B(03681):SM17用于治疗IBD的IND获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717630","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613717630?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:01","pubTimestamp":1771941713,"startTime":"0","endTime":"0","summary":"智通财经APP讯,中国抗体-B 公布,于2026年2月24日,公司同类首创治疗产品SM17用于治疗炎症性肠病患者的新药临床试验申请已获中国国家药品监督管理局批准。公司已完成针对使用SM17皮下注射剂型的健康志愿者I期桥接实验的随访。该机制使SM17成为UC有前景的治疗候选药物,其中已证实IL-25发挥促炎作用。公司进一步认为,靶向2型炎性通路上游调控因子的治疗策略可支持SM17成为用于治疗AD及IBD的具差异化、安全性更佳且有效的治疗选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IND","BK1574","IBD","03681"],"gpt_icon":0},{"id":"2613675997","title":"一份报告砸崩印度IT!AI冲击担忧发酵,印度软件股遭遇大规模抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2613675997","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613675997?lang=zh_cn&edition=full","pubTime":"2026-02-24 15:03","pubTimestamp":1771916638,"startTime":"0","endTime":"0","summary":"在近日研究公司Citrini Research发布报告后,市场对人工智能冲击相关企业的担忧进一步放大,印度软件服务类股遭遇深度抛售。据了解,Citrini发表的报告详细分析AI可能为全球经济多个领域带来潜在风险,设想2028年AI引发白领失业、消费萎缩,以及由软件支援的贷款出现违约、经济陷入收缩的情况。投资者担忧,Anthropic等公司推出的AI工具将持续挤压行业利润率。该报告同样冲击美国市场,物流配送、支付及软件类股普遍走低,$IBM$股价遭遇25年来最大单日跌幅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"一份报告砸崩印度IT!AI冲击担忧发酵,印度软件股遭遇大规模抛售","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VGT","INCO","PIN","BK4588","SMIN","INDL","EPI","INDY","INXX","IMVP","MNDmain","NFTY","INDA","IFN","FLIN","SCIN","BK4585","IND","IBN"],"gpt_icon":0},{"id":"2613753336","title":"长风药业(02652):国家药监局受理ICF004的IND申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2613753336","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613753336?lang=zh_cn&edition=full","pubTime":"2026-02-24 06:12","pubTimestamp":1771884770,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长风药业 发布公告,本公司自主研发的吸入粉雾剂候选药物ICF004(产品)的新药临床试验申请(该申请)已获中国国家药品监督管理局受理。ICF004拟用于治疗进行性纤维化间质性肺病,该疾病领域包括特发性肺纤维化及进行性肺纤维化等危及生命的适应症。在已完成的临床前研究中,ICF004经吸入给药后呈现差异化的分布特征,表现为肺组织高暴露量及低全身暴露量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02652","IND"],"gpt_icon":0},{"id":"2612347876","title":"美国FDA局长抱怨:美国在早期药物研发方面正落后于中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2612347876","media":"观察者网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612347876?lang=zh_cn&edition=full","pubTime":"2026-02-19 08:12","pubTimestamp":1771459949,"startTime":"0","endTime":"0","summary":"美国食品药品管理局局长马蒂·马卡里日前警告称,在早期药物研发方面,美国正落后于中国,并呼吁进行改革,以简化新疗法临床试验的启动流程。当地时间2月18日,在接受美国消费者新闻与商业频道采访时,马卡里特别指出了导致美国在早期药物试验方面落后的三大瓶颈。据悉,这正吸引国际大型制药商将更多研发资金投入中国,在美国政客中引发忧虑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8qrf75YHOQH","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["LU0154245673.USD","LU1496350502.SGD","BK4548","SG9999004253.SGD","BK4585","LU0320765489.SGD","LU0648001328.SGD","LU0980610538.SGD","LU1201861249.SGD","LU0070302665.USD","SG9999001077.SGD","CBRE","LU0130517989.USD","LU0208291251.USD","IND","LU0130102774.USD","BK4588","LU0154245756.USD","LABU","BK4079","LU1496350171.SGD","LU0477156953.USD"],"gpt_icon":0},{"id":"2611102569","title":"野村:印度央行在2027年前不太可能降息","url":"https://stock-news.laohu8.com/highlight/detail?id=2611102569","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611102569?lang=zh_cn&edition=full","pubTime":"2026-02-16 17:18","pubTimestamp":1771233480,"startTime":"0","endTime":"0","summary":"野村(Nomura)研究分析师称,印度央行预计将维持利率不变,至少到2027年底。这些分析师在一份报告中写道,新CPI系列下的通胀走强以及更积极的增长前景意味着印度央行不太可能很快降息。\n 这些分析师补充说,通胀轨迹基本未变,新的CPI系列预计不会改变印度央行的看法,即基本通胀依然温和,且牢牢锚定在其4%的中期目标。这些分析师称,与美国和欧盟的贸易协议、印度的“扩张性“预算以及以往降息的滞后效应,也都为2027财年更强劲的GDP增长奠定了基础。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:刘明亮","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/2026-02-16/doc-inhmzfsf9971334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IND","BK4588","FLIN","IMVP","EPI","INDA","INDY","HK0000934320.USD","PIN","INDL","SCIN","BK4585","BK4523","SMIN","NFTY"],"gpt_icon":0},{"id":"2611017176","title":"基石药业:CS2009II期临床试验申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2611017176","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611017176?lang=zh_cn&edition=full","pubTime":"2026-02-16 08:17","pubTimestamp":1771201057,"startTime":"0","endTime":"0","summary":"【基石药业:CS2009II期临床试验申请获美国FDA批准】2月16日,基石药业在港交所公告,公司核心资产CS2009(PD-1/VEGF/CTLA-4三特异性抗体)用于晚期实体瘤的II期新药临床试验(IND)申请已经获得美国食品药品监督管理局(FDA)批准。CS2009用于晚期实体瘤的II期IND申请获FDA批准,标志着这一创新免疫疗法的全球开发取得重要进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202602163651161217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IND"],"gpt_icon":0},{"id":"2610600638","title":"九源基因(02566):JY54注射液IND申请获CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610600638","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610600638?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:56","pubTimestamp":1770627414,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九源基因 发布公告,公司自主开发的化学1类创新药JY54 注射液新药临床试验申请,已获国家药品监督管理局药品审评中心正式受理。JY54注射液是公司自主研发的一款长效胰淀素类似物。此外,在与已上市肥胖治疗药物的联合应用研究中,JY54注射液展现出显著的药物协同潜力。基于其分子设计特点及作用机制分析,JY54注射液有望支持长效给药方案,并在体重管理领域展现差异化的临床应用潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4017","02566","BK1161","LU1223083913.SGD","IND","LU1223082196.USD","CDE","LU1223082519.USD"],"gpt_icon":0},{"id":"2609095558","title":"亚盛医药BTK降解剂APG-3288新药临床申请(IND)获CDE许可,全球临床开发再提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2609095558","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609095558?lang=zh_cn&edition=full","pubTime":"2026-02-06 10:04","pubTimestamp":1770343440,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年2月6日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布,公司自主研发的原创新一代布鲁顿酪氨酸激酶靶向蛋白降解剂APG-3288的新药临床申请日前已获国家药品监督管理局药品审评中心许可,拟开发用于治疗复发/难治性血液系统恶性肿瘤。此前,该药物已获美国FDA许可开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4882324_ZH82324_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1223082196.USD","BK4017","BK4144","LU2125909916.SGD","LU2125909759.SGD","BK4129","BK4139","BK1161","BK1574","LU1223082519.USD","LU1923622291.USD","TK","IND","LU1223083913.SGD","06855","APG","AAPG","CDE"],"gpt_icon":0},{"id":"2608824493","title":"友芝友生物-B(02496):M 701取得FDA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608824493","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608824493?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:09","pubTimestamp":1770113353,"startTime":"0","endTime":"0","summary":"智通财经APP讯,友芝友生物-B 发布公告,于2026年1月31日,注射用重组抗上皮细胞黏附分子和分化簇3人鼠嵌合双特异性抗体获美国食品药物管理局临床试验申请批准,标志着这款针对恶性胸腔积液的创新疗法迈入国际化临床开发新阶段,为全球患者带来新希望。M 701精准靶向Ep CAM和CD3,其中Ep CAM在上皮来源恶性胸腔积液肿瘤细胞中高频表达,是关键治疗靶点;CD3可激活机体抗肿瘤免疫,二者协同实现精准治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","IND","BK1161"],"gpt_icon":0},{"id":"2602347075","title":"这家药企又一款新药临床申请获FDA许可,国际化发展持续加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2602347075","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602347075?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:42","pubTimestamp":1767858161,"startTime":"0","endTime":"0","summary":"近日,亚盛医药宣布BTK降解剂APG-3288的新药临床申请获美国FDA许可,将开展其治疗复发/难治B细胞恶性肿瘤的临床研究。截至目前,公司已共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。业内预计,随着亚盛医药重磅品种临床的持续推进,以及与跨国药企及顶尖学术机构的深度合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108160110a4ab1664&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108160110a4ab1664&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ASPHF","IND"],"gpt_icon":0},{"id":"2601336363","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601336363","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601336363?lang=zh_cn&edition=full","pubTime":"2026-01-08 10:10","pubTimestamp":1767838222,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,康宁杰瑞制药-B涨超6%,截至发稿,涨6.76%,报10.89港元,成交额1041.75万港元。消息面上,近日,康宁杰瑞制药-B发布公告,JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床试验的新药临床试验申请,已获国家药品监督管理局药品审评中心正式受理。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。铂类药物的选择和是否联用贝伐珠单抗将由研究者根据患者的具体情况决定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2601890033","title":"康希诺:2025年公司4款候选产品已获得批准IND/NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890033","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601890033?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:32","pubTimestamp":1767706320,"startTime":"0","endTime":"0","summary":"产品获批及研发端,2025年公司4款候选产品已获得批准IND/NDA,以及启动2个新的临床试验,以2026年设置的业绩考核目标A档来看,2026年至少包括5款候选产品获得批准IND、获得批准NDA,以及至少启动2个新的临床试验。目前也是在按既定的研发节奏推进,公司也会和药监、中检院及临床试验合作方等积极沟通,以期顺利推进相应候选产品的研发里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688185","IND"],"gpt_icon":0},{"id":"2601071879","title":"港股异动 | 复宏汉霖(02696)现涨近9% 公司旗下三款实体瘤创新药IND同期获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601071879","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601071879?lang=zh_cn&edition=full","pubTime":"2026-01-05 11:02","pubTimestamp":1767582152,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,复宏汉霖(02696)现涨近9%,截至发稿,涨8.62%,报63.65港元,成交额2904.28万港元。消息面上,12月30日,复宏汉霖宣布,公司三款潜力创新分子——基于自研T细胞衔接器(TCE)平台开发的DLL3xDLL3xCD3xCD28四特异性TCE HLX3901、潜在同类最优(BIC)的新型KAT6A/B口服小分子抑制剂HLX97、以及潜在同类首创(FIC)的B7H3-唾液酸酶融合蛋白HLX316的新药临床试验申请均已获得国家药品监督管理局受理。以上三款产品皆拟用于实体肿瘤的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","159992","02696","HK0000165453.HKD","IND","06978"],"gpt_icon":0},{"id":"2601785620","title":"歌礼制药-B(01672)宣布ASC30在糖尿病受试者中的 13周II期研究IND获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2601785620","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601785620?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:13","pubTimestamp":1767572009,"startTime":"0","endTime":"0","summary":"智通财经APP讯,歌礼制药-B 公布,近期已获得美国食品药品监督管理局 对其口服小分子GLP-1,ASC30,在糖尿病受试者中的II期研究的新药临床试验的批准。该II期研究是一项为期13周、随机、双盲、安慰剂对照及多中心的研究,旨在评估ASC30在2型糖尿病受试者中的疗效、安全性和耐受性。歌礼已于近期完成其评估口服小分子GLP-1受体激动剂ASC30治疗肥胖症的13周II期研究。在ASC30用于治疗肥胖或超重的II期研究中,因不良事件导致的总体停药率为4.8%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f1a65319f224684be7c4d1ad3324a2f2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01672","BK1574","IND","BK1191","BK1161","01477"],"gpt_icon":0},{"id":"2595670427","title":"海思科(002653.SZ):“HSK50042”、“HSK55879”创新药IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2595670427","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595670427?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:20","pubTimestamp":1767082829,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科 发布公告,公司子公司上海海思盛诺医药科技有限公司于近日收到国家药品监督管理局下发的《受理通知书》,涉及产品:“HSK50042”、“HSK55879”。本次申请为HSK50042片在呼吸系统疾病领域中又一新适应症的临床试验申请,有望为呼吸疾病患者提供一种高效、安全的新型治疗选择。HSK55879片是公司自主研发的具有独立知识产权的口服小分子激动剂药物,拟用于代谢系统疾病的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0077","159992","BK0188","06978","BK1574","BK0033","IND","002653","BK1161","BK0239"],"gpt_icon":0},{"id":"2595040206","title":"康宁杰瑞制药-B(09966):JSKN033的一项II期临床试验的IND申请获CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2595040206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595040206?lang=zh_cn&edition=full","pubTime":"2025-12-29 12:17","pubTimestamp":1766981869,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康宁杰瑞制药-B 发布公告,JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床试验的新药临床试验申请,已获国家药品监督管理局药品审评中心正式受理。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。铂类药物的选择和是否联用贝伐珠单抗将由研究者根据患者的具体情况决定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDE","BK1161","LU1223083913.SGD","IND","BK1574","BK4017","LU1223082196.USD","LU1223082519.USD","09966"],"gpt_icon":0},{"id":"2593471543","title":"友芝友生物-B(02496):Y225(艾美赛珠单抗注射液)取得NMPA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593471543","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593471543?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:37","pubTimestamp":1766576227,"startTime":"0","endTime":"0","summary":"智通财经APP讯,友芝友生物-B 发布公告,于2025年12月23日,其生物类似药Y225的临床试验申请已获中华人民共和国国家药品监督管理局批准。Y225是一种用于治疗A型血友病的双特异性抗体舒友立乐生物类似药。本次获批的临床试验是一项在健康成年人中进行的随机、双盲、单剂量、平行比较舒友立乐与Y225在健康男性受试者中的生物等效性临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IND","02496"],"gpt_icon":0},{"id":"2593418484","title":"和誉-B(02256):口服小分子KRAS G12D抑制剂ABSK141的IND获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418484","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593418484?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:02","pubTimestamp":1766534531,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B(02256)发布公告,公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布,其口服、高活性、高选择性小分子KRAS G12D抑制剂ABSK141用于治疗携带KRAS G12D突变的晚期实体瘤患者的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","BK1161","LU2476274720.SGD","LU2488822045.USD","IE00BPRC5H50.USD","LU2778985437.USD","IE00B5MMRT66.SGD","IND","02256","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2593485369","title":"海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485369","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485369?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:36","pubTimestamp":1766396197,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科 发布公告,公司子公司辽宁海思科制药有限公司于近日收到国家药品监督管理局下发的《受理通书》,涉及药品:“HSK46575”。本次获得受理的为本品联合奥拉帕利片或联合多西他赛和泼尼松片用于前列腺癌的治疗适应症的临床试验申请。HSK46575片是公司自主研发的一种口服、强效和高选择性的小分子抑制剂,拟用于前列腺癌的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK0028","BK1161","159992","BK0239","BK0033","002653","BK1574","BK0188","06978","BK0077"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ing.com","stockEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.0345},{"period":"3month","weight":-0.0313},{"period":"6month","weight":-0.023},{"period":"ytd","weight":-0.0141}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"荷兰国际集团是在1991年由荷兰国民人寿保险公司和荷兰邮政银行集团合并组成的综合性财政金融集团。据美国财富(FORTUNES)杂志统计,以资产净值计算,荷兰国际集团位居全球500家大企业的第64位。在提供综合性金融财经业务方面(银行与保险业务),居世界第三位。目前,该集团在世界上65个国家和地区设有分支机构,雇员超过10万人。2000年,该集团取得税后净利润49亿欧元,同比增长24%。截至2000年底,集团资产总额达5030亿欧元。 管理结构: 在董事会下面设有四个管理运作核心,荷兰总部;国际金融财经业务部;企业和资本市场部;资产管理部。 集团总部:负责荷兰本国市场上的全部保险和银行业务。 国际金融财经业务部:所有荷兰本土以外的国际保险业、零售银行业和商业银行业的运作皆由该中心管理。其保险业务划分三大地区:欧洲和拉丁美洲、北美洲、亚澳地区。银行业务则由中心统一管理。 企业及资本市场部:所有国际货币和资本市场管理部门都由该部门管理。包括国际银行网络以及金融产品、贸易、销售、投资银行、企业银行、风险管理及调研的各项业务。 资产管理部:该部门承担企业投资者的资产和帐目管理、提供个人国际银行服务以及集团公司的保险业务的资产管理。房地产业务和信托业务也属于这个部门管理。该部门同时管理荷兰国际集团各个公司的投资基金。","yearOnYearQuotes":[{"month":1,"riseRate":0.857143,"avgChangeRate":0.027152},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.031592},{"month":3,"riseRate":0.785714,"avgChangeRate":0.035422},{"month":4,"riseRate":0.571429,"avgChangeRate":0.017359},{"month":5,"riseRate":0.285714,"avgChangeRate":0.00595},{"month":6,"riseRate":0.714286,"avgChangeRate":0.006634},{"month":7,"riseRate":0.785714,"avgChangeRate":0.023298},{"month":8,"riseRate":0.4,"avgChangeRate":-0.016348},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.024108},{"month":10,"riseRate":0.785714,"avgChangeRate":0.022259},{"month":11,"riseRate":0.357143,"avgChangeRate":-0.033495},{"month":12,"riseRate":0.642857,"avgChangeRate":0.020836}],"exchange":"NASDAQ","name":"Xtrackers Nifty 500 India ETF","nameEN":"Xtrackers Nifty 500 India ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xtrackers Nifty 500 India ETF(IND)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Xtrackers Nifty 500 India ETF(IND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Xtrackers Nifty 500 India ETF,IND,Xtrackers Nifty 500 India ETF股票,Xtrackers Nifty 500 India ETF股票老虎,Xtrackers Nifty 500 India ETF股票老虎国际,Xtrackers Nifty 500 India ETF行情,Xtrackers Nifty 500 India ETF股票行情,Xtrackers Nifty 500 India ETF股价,Xtrackers Nifty 500 India ETF股市,Xtrackers Nifty 500 India ETF股票价格,Xtrackers Nifty 500 India ETF股票交易,Xtrackers Nifty 500 India ETF股票购买,Xtrackers Nifty 500 India ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xtrackers Nifty 500 India ETF(IND)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Xtrackers Nifty 500 India ETF(IND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}